• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

盐皮质激素受体拮抗剂可预防代谢应激与慢性肾脏病对小鼠肾纤维化和炎症的协同作用。

Mineralocorticoid Receptor Antagonism Prevents the Synergistic Effect of Metabolic Challenge and Chronic Kidney Disease on Renal Fibrosis and Inflammation in Mice.

作者信息

Palacios-Ramirez Roberto, Lima-Posada Ixchel, Bonnard Benjamin, Genty Marie, Fernandez-Celis Amaya, Hartleib-Geschwindner Judith, Foufelle Fabienne, Lopez-Andres Natalia, Bamberg Krister, Jaisser Frederic

机构信息

Centre de Recherche des Cordeliers, Team Diabetes, Metabolic Diseases and Comorbidities, Sorbonne Université, Inserm, Université de Paris, Paris, France.

Cardiovascular Translational Research, Navarrabiomed (Miguel Servet Foundation), Instituto de Investigación Sanitaria de Navarra (IdiSNA), Pamplona, Spain.

出版信息

Front Physiol. 2022 Apr 7;13:859812. doi: 10.3389/fphys.2022.859812. eCollection 2022.

DOI:10.3389/fphys.2022.859812
PMID:35464084
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9022039/
Abstract

Obesity and/or metabolic diseases are frequently associated with chronic kidney disease and several factors associated with obesity may contribute to proteinuria and extracellular matrix production. Mineralocorticoid receptor antagonists have proven their clinical efficacy in diabetic kidney disease with preclinical data suggesting that they may also be efficient in non-diabetic chronic kidney disease associated to metabolic diseases. In the present study we developed a novel mouse model combining severe nephron reduction and High Fat Diet challenge that led to chronic kidney disease with metabolic alterations. We showed that the Mineralocorticoid Receptor antagonist canrenoate improved metabolic function, reduced albuminuria and prevented the synergistic effect of high fat diet on renal fibrosis and inflammation in chronic kidney disease mice.

摘要

肥胖和/或代谢性疾病常与慢性肾脏病相关，一些与肥胖相关的因素可能导致蛋白尿和细胞外基质生成。盐皮质激素受体拮抗剂已在糖尿病肾病中证明了其临床疗效，临床前数据表明它们在与代谢性疾病相关的非糖尿病慢性肾脏病中可能也有效。在本研究中，我们构建了一种新型小鼠模型，该模型结合了严重的肾单位减少和高脂饮食刺激，从而导致伴有代谢改变的慢性肾脏病。我们发现，盐皮质激素受体拮抗剂坎利酸钾可改善代谢功能、减少蛋白尿，并防止高脂饮食对慢性肾脏病小鼠肾纤维化和炎症的协同作用。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b237/9022039/19e48616b2dc/fphys-13-859812-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b237/9022039/7e61e41de932/fphys-13-859812-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b237/9022039/6b691d571057/fphys-13-859812-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b237/9022039/b56c57b5046d/fphys-13-859812-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b237/9022039/19e48616b2dc/fphys-13-859812-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b237/9022039/7e61e41de932/fphys-13-859812-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b237/9022039/6b691d571057/fphys-13-859812-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b237/9022039/b56c57b5046d/fphys-13-859812-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b237/9022039/19e48616b2dc/fphys-13-859812-g004.jpg

相似文献

1
Mineralocorticoid Receptor Antagonism Prevents the Synergistic Effect of Metabolic Challenge and Chronic Kidney Disease on Renal Fibrosis and Inflammation in Mice.盐皮质激素受体拮抗剂可预防代谢应激与慢性肾脏病对小鼠肾纤维化和炎症的协同作用。
Front Physiol. 2022 Apr 7;13:859812. doi: 10.3389/fphys.2022.859812. eCollection 2022.
2
Mineralocorticoid receptor blockade prevents Western diet-induced diastolic dysfunction in female mice.盐皮质激素受体阻断可预防西式饮食诱导的雌性小鼠舒张功能障碍。
Am J Physiol Heart Circ Physiol. 2015 May 1;308(9):H1126-35. doi: 10.1152/ajpheart.00898.2014. Epub 2015 Mar 6.
3
Mineralocorticoid receptor antagonists and kidney diseases: pathophysiological basis.醛固酮受体拮抗剂与肾脏疾病：病理生理学基础。
Kidney Int. 2019 Aug;96(2):302-319. doi: 10.1016/j.kint.2019.02.030. Epub 2019 Mar 13.
4
Aldosterone deficiency and mineralocorticoid receptor antagonism prevent angiotensin II-induced cardiac, renal, and vascular injury.醛固酮缺乏和盐皮质激素受体拮抗剂可预防血管紧张素 II 诱导的心脏、肾脏和血管损伤。
Kidney Int. 2012 Sep;82(6):643-51. doi: 10.1038/ki.2012.170. Epub 2012 May 23.
5
Direct Blood Pressure-Independent Anti-Fibrotic Effects by the Selective Nonsteroidal Mineralocorticoid Receptor Antagonist Finerenone in Progressive Models of Kidney Fibrosis.选择性非甾体盐皮质激素受体拮抗剂非奈利酮在进行性肾纤维化模型中的直接血压非依赖性抗纤维化作用。
Am J Nephrol. 2021;52(7):588-601. doi: 10.1159/000518254. Epub 2021 Aug 30.
6
Clinical perspective-evolving evidence of mineralocorticoid receptor antagonists in patients with chronic kidney disease and type 2 diabetes.临床视角——盐皮质激素受体拮抗剂在慢性肾脏病合并2型糖尿病患者中的循证进展
Kidney Int Suppl (2011). 2022 Apr;12(1):27-35. doi: 10.1016/j.kisu.2021.11.005. Epub 2022 Mar 18.
7
Effect of a novel nonsteroidal selective mineralocorticoid receptor antagonist, esaxerenone (CS-3150), on blood pressure and renal injury in high salt-treated type 2 diabetic mice.新型非甾体选择性盐皮质激素受体拮抗剂依斯巴伦诺（CS-3150）对高盐处理的 2 型糖尿病小鼠血压和肾脏损伤的影响。
Hypertens Res. 2019 Jun;42(6):892-902. doi: 10.1038/s41440-019-0211-0. Epub 2019 Jan 21.
8
Role of mineralocorticoid receptor antagonists in kidney diseases.盐皮质激素受体拮抗剂在肾脏疾病中的作用。
Drug Dev Res. 2021 May;82(3):341-363. doi: 10.1002/ddr.21760. Epub 2020 Nov 12.
9
Delayed spironolactone administration prevents the transition from acute kidney injury to chronic kidney disease through improving renal inflammation.延迟螺内酯给药通过改善肾脏炎症来防止急性肾损伤向慢性肾脏病的转变。
Nephrol Dial Transplant. 2019 May 1;34(5):794-801. doi: 10.1093/ndt/gfy246.
10
Role of mineralocorticoid receptor/Rho/Rho-kinase pathway in obesity-related renal injury.矿物质皮质激素受体/ Rho/ Rho-激酶通路在肥胖相关性肾损伤中的作用。
Int J Obes (Lond). 2012 Aug;36(8):1062-71. doi: 10.1038/ijo.2011.232. Epub 2011 Dec 20.

引用本文的文献

1
Mineralocorticoid Receptor and Sleep Quality in Chronic Kidney Disease.醛固酮受体与慢性肾脏病患者的睡眠质量。
Int J Mol Sci. 2024 Nov 16;25(22):12320. doi: 10.3390/ijms252212320.
2
Nonsteroidal Mineralocorticoid Receptor Antagonist Finerenone Improves Diastolic Dysfunction in Preclinical Nondiabetic Chronic Kidney Disease.非甾体类盐皮质激素受体拮抗剂非奈利酮可改善非糖尿病慢性肾脏病的舒张功能障碍。
J Am Heart Assoc. 2024 Jun 18;13(12):e032971. doi: 10.1161/JAHA.123.032971. Epub 2024 Jun 6.
3
Fibrosis in Chronic Kidney Disease: Pathophysiology and Therapeutic Targets.

本文引用的文献

1
Mineralocorticoid receptor antagonists in diabetic kidney disease - mechanistic and therapeutic effects.糖尿病肾病中的盐皮质激素受体拮抗剂——作用机制与治疗效果
Nat Rev Nephrol. 2022 Jan;18(1):56-70. doi: 10.1038/s41581-021-00490-8. Epub 2021 Oct 21.
2
Hydrogen Sulfide Attenuated Sepsis-Induced Myocardial Dysfunction Through TLR4 Pathway and Endoplasmic Reticulum Stress.硫化氢通过Toll样受体4信号通路和内质网应激减轻脓毒症诱导的心肌功能障碍。
Front Physiol. 2021 Jun 9;12:653601. doi: 10.3389/fphys.2021.653601. eCollection 2021.
3
Fibrosis in Chronic Kidney Disease: Pathogenesis and Consequences.
慢性肾脏病中的纤维化：病理生理学与治疗靶点
J Clin Med. 2024 Mar 25;13(7):1881. doi: 10.3390/jcm13071881.
4
Role of the CCL5 and Its Receptor, CCR5, in the Genesis of Aldosterone-Induced Hypertension, Vascular Dysfunction, and End-Organ Damage.CCL5 及其受体 CCR5 在醛固酮诱导的高血压、血管功能障碍和靶器官损伤中的作用。
Hypertension. 2024 Apr;81(4):776-786. doi: 10.1161/HYPERTENSIONAHA.123.21888. Epub 2024 Jan 19.
5
The role of a novel mineralocorticoid receptor antagonist, finerenone, in chronic kidney disease: mechanisms and clinical advances.新型盐皮质激素受体拮抗剂非奈利酮在慢性肾脏病中的作用：作用机制与临床进展
Clin Exp Nephrol. 2024 Feb;28(2):125-135. doi: 10.1007/s10157-023-02413-2. Epub 2023 Oct 17.
6
Treatment with fibroblast growth factor 19 increases skeletal muscle fiber size, ameliorates metabolic perturbations and hepatic inflammation in 5/6 nephrectomized mice.成纤维细胞生长因子 19 的治疗可增加 5/6 肾切除小鼠的骨骼肌纤维大小，改善代谢紊乱和肝炎症。
Sci Rep. 2023 Apr 4;13(1):5520. doi: 10.1038/s41598-023-31874-4.
7
Benefits of the Non-Steroidal Mineralocorticoid Receptor Antagonist Finerenone in Metabolic Syndrome-Related Heart Failure with Preserved Ejection Fraction.非甾体类盐皮质激素受体拮抗剂费列罗酮在射血分数保留的代谢综合征相关心力衰竭中的作用。
Int J Mol Sci. 2023 Jan 28;24(3):2536. doi: 10.3390/ijms24032536.
8
Finerenone, a Non-Steroidal Mineralocorticoid Receptor Antagonist, Reduces Vascular Injury and Increases Regulatory T-Cells: Studies in Rodents with Diabetic and Neovascular Retinopathy.非奈利酮，一种非甾体盐皮质激素受体拮抗剂，可减少血管损伤并增加调节性 T 细胞：在糖尿病和新生血管性视网膜病变的啮齿动物中的研究。
Int J Mol Sci. 2023 Jan 25;24(3):2334. doi: 10.3390/ijms24032334.
9
Fisetin reduces the senescent tubular epithelial cell burden and also inhibits proliferative fibroblasts in murine lupus nephritis.非瑟酮可减少狼疮性肾炎小鼠衰老肾小管上皮细胞的负担，还可抑制增殖性成纤维细胞。
Front Immunol. 2022 Nov 17;13:960601. doi: 10.3389/fimmu.2022.960601. eCollection 2022.
10
Mineralocorticoid Receptor Activation in Vascular Insulin Resistance and Dysfunction.矿皮质激素受体在血管胰岛素抵抗和功能障碍中的激活作用。
Int J Mol Sci. 2022 Aug 11;23(16):8954. doi: 10.3390/ijms23168954.
慢性肾脏病中的纤维化：发病机制与后果。
Int J Mol Sci. 2021 Jan 2;22(1):408. doi: 10.3390/ijms22010408.
4
Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes.非奈利酮对 2 型糖尿病患者慢性肾脏病结局的影响。
N Engl J Med. 2020 Dec 3;383(23):2219-2229. doi: 10.1056/NEJMoa2025845. Epub 2020 Oct 23.
5
Finerenone and Cardiovascular Outcomes in Patients With Chronic Kidney Disease and Type 2 Diabetes.非奈利酮与慢性肾脏病合并 2 型糖尿病患者的心血管结局。
Circulation. 2021 Feb 9;143(6):540-552. doi: 10.1161/CIRCULATIONAHA.120.051898. Epub 2020 Nov 16.
6
Apararenone in patients with diabetic nephropathy: results of a randomized, double-blind, placebo-controlled phase 2 dose-response study and open-label extension study.阿帕雷酮治疗糖尿病肾病患者的疗效：一项随机、双盲、安慰剂对照的 2 期剂量反应研究和开放标签扩展研究结果。
Clin Exp Nephrol. 2021 Feb;25(2):120-130. doi: 10.1007/s10157-020-01963-z. Epub 2020 Sep 24.
7
The novel non-steroidal MR antagonist finerenone improves metabolic parameters in high-fat diet-fed mice and activates brown adipose tissue via AMPK-ATGL pathway.新型非甾体类 MR 拮抗剂非奈利酮通过 AMPK-ATGL 通路改善高脂肪饮食喂养小鼠的代谢参数并激活棕色脂肪组织。
FASEB J. 2020 Sep;34(9):12450-12465. doi: 10.1096/fj.202000164R. Epub 2020 Jul 30.
8
Phosphoinositide 3-kinase γ deficiency attenuates kidney injury and fibrosis in angiotensin II-induced hypertension.磷酸肌醇 3-激酶 γ 缺乏可减轻血管紧张素 II 诱导的高血压引起的肾脏损伤和纤维化。
Nephrol Dial Transplant. 2020 Sep 1;35(9):1491-1500. doi: 10.1093/ndt/gfaa062.
9
Revisiting Experimental Models of Diabetic Nephropathy.重新审视糖尿病肾病的实验模型。
Int J Mol Sci. 2020 May 19;21(10):3587. doi: 10.3390/ijms21103587.
10
Pathophysiologic mechanisms in diabetic kidney disease: A focus on current and future therapeutic targets.糖尿病肾病的病理生理机制：关注当前和未来的治疗靶点。
Diabetes Obes Metab. 2020 Apr;22 Suppl 1:16-31. doi: 10.1111/dom.13969.